Investigation of Certain Manifestations of Bystander Response Phenomenon That May Affect the Development of Human Cancer Pathology

Maria A Pilinska
2021 Biomedical Journal of Scientific & Technical Research  
Results It was found that co-cultivation of non-irradiated blood cells received from untreated CLL patients (cells-inductors) jointly with intact PBL received from conditionally healthy individuals (bystander cells) leads to significant increase (p < 0.01) in the meangroup frequency of chromosomal aberrations in the bystander cells -from 1.52 ± 0.30 per 100 metaphases (at the separate cultivation) to 3.31 ± 0.50 per 100 metaphases (at the joint cultivation) which confirmed the development of
more » ... e development of TIBE [8]. Under co-cultivation of irradiated in vitro malignant cells-inductors jointly with normal bystander cells the mean group frequency of chromosome aberrations in the bystander cells (5.18 ± 0.51 per 100 metaphases) became significantly higher than their background level (1.52 ± 0.30 per 100 metaphases, p < 0.001)) and their level at only TIBE manifestation (3.31 ± 0.50 per 100 metaphases, p < 0.01) [9]. The data obtained testify the reality of synergism between tumorinduced and radiation-induced bystander effects. Co-cultivation of irradiated in vitro blood cells of CLL patients with intact PBL of relatively healthy persons leads to the significantly decrease of chromosomal aberrations frequency in cells-inductors (from 12,88 ± 1,16 till 9,56 ± 1,01 per 100 metaphases, p < 0.01), which is similar to the manifestation of rescue effect [10]. Conclusion The results of our experimental studies concerning the interaction between irradiated or non-irradiated malignantly transformed and intact normal human somatic cells confirm the possibility of development the dangerous for cancer patients' certain manifestations of the bystander response phenomenon (TIBE, RIBE, RIRE), which requires further research for improvement the protocols of cancer treatment through the creation of more effective and less toxic therapy regimens.
doi:10.26717/bjstr.2021.33.005434 fatcat:oix72qn2pbbudivo6xydl7id6q